Multiple sclerosis (MS) is a neurological disease that affects about 1 million people in the United States. Your brain contains a type of cell called a neuron, and neurons are coated in a layer of ...

Join the School of Medicine’s Department of Population and Quantitative Health Sciences to learn about the options available with an MS in clinical research. A webinar will be held Sunday, Dec. 20, at ...

Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and ...

The immune system’s reaction to the common Epstein-Barr virus can ultimately damage the brain and contribute to multiple ...

A new University of Toronto-led study has discovered a possible biomarker linked to multiple sclerosis (MS) disease ...

Quantum Biopharma expects data from two now-completed, FDA-requested toxicology studies to support clinical testing of its ...

"Routine cognitive assessments should be integrated into clinical practice, allowing for early detection and intervention." — Dejan Jakimovski, MD, PhD, Research Assistant Professor, Department of ...

Dr. Bhargava is an Associate Professor of Neurology at Johns Hopkins University School of Medicine. After obtaining his medical degree from Christian Medical College in Vellore, India, Dr. Bhargava ...

MS is the most common demyelinating disease with an estimated prevalence of 3 in 1000 in the United States. It affects approximately 740,000 individuals in the United States and 2.5 million globally.

Regulatory and clinical roadblocks have set back its oral BTK inhibitor tolebrutinib, but the drug class still has many ...